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Vitamin D is a potent steroid hormone that induces widespread changes in gene
expression and controls key biological pathways. Here we review pathophysiology of
vitamin D with particular reference to COVID-19 and pancreatic cancer. Utility as a
therapeutic agent is limited by hypercalcemic effects and attempts to circumvent this
problem have used vitamin D superagonists, with increased efficacy and reduced
calcemic effect. A further caveat is that vitamin D mediates multiple diverse effects.
Some of these (anti-fibrosis) are likely beneficial in patients with COVID-19 and pancreatic
cancer, whereas others (reduced immunity), may be beneficial through attenuation of the
cytokine storm in patients with advanced COVID-19, but detrimental in pancreatic cancer.
Vitamin D superagonists represent an untapped resource for development of effective
therapeutic agents. However, to be successful this approach will require agonists with
high cell-tissue specificity.
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Vitamin D is a steroid hormone with well-characterized effects on bone metabolism and calcium
homeostasis. More recently, attention has focused upon non-classical effects, including important
roles in regulation of the immune response and lung function and less well described effects in
multiple additional tissues such as the cardiovascular system (1–3).
Vitamin D deficiency appears to be widespread globally, although significant data gaps exist for
low-income countries (4, 5). Deficiency has been defined as serum calcidiol (25 OH vitamin D) less
than 50nmol/L in the USA. Insufficiency occurs between 50-75 nmol/L. To reduce the risk of
infectious disease, the US Endocrine Society recommended serum calcidiol should be above
75nmol/L (6). Approximately 40% of Europeans live with moderate deficiency (below the
50nmol/L cut off) and 5% of the US population have severe deficiency with serum levels less
than 30nmol/L (5, 7). Serum calcidiol levels show seasonal variation and at the end of winter, 36% of
young adults in the USA have insufficient (70 ± 25nmol/L) vitamin D (8).
In developed countries, deficiency appears more common within specific populations. In the UK
this includes BAME (Black, Asian and Minority Ethnic), elderly and obese individuals (9, 10).
Low serum calcidiol has been linked to increased susceptibility to a variety of diseases, including
renal, dermatological, cardiovascular and autoimmune disease, infections and cancer (11, 12).n.org March 2021 | Volume 12 | Article 6442981
Easty et al. Vitamin D From COVID to CancerEvidence suggests that vitamin Dmay protect against COVID-19
infection and decrease severity of symptoms in patients
hospitalized with severe viral pneumonia. This might involve
vitamin D inhibition of the cytokine storm and anti-fibrotic
effects in the acute respiratory distress syndrome (ARDS)
responsible for much mortality in COVID-19 (3, 13, 14).
Here we briefly review the physiology of vitamin D and
regulation of target gene transcription. We describe activated
vitamin D receptor (VDR) binding to DNA elements within
promoters of target genes in association with coactivators and
corepressors. Next, we discuss vitamin D superagonist (VDSA)
interaction with the normal process of transcription to
supercharge target gene expression. Then, in the main part of
this review, we describe the pathophysiology of vitamin D with
particular reference to COVID-19 and pancreatic cancer. Finally,
we discuss approaches for the development of therapeutically
useful VDSAs in some common human diseases.VITAMIN D PHYSIOLOGY
The physiology of vitamin D has been extensively reviewed (3,
15) and is only briefly considered here. Cholecalciferol is
obtained from ultraviolet light-induced cutaneous synthesis
and to a lesser extent from diet. Within the skin, cholesterol
precursor 7-dehydrocholesterol is converted to vitamin D3,
which is hydroxylated to 25(OH)-D3 (calcidiol) in the liver and
then to the act ive metabol i te , 1 ,25(OH)2-D3 (1a ,
25-dihydroxycholecalciferol, (calcitriol) in the kidney.
Importantly, conversion of calcidiol into calcitriol also occurs
within multiple tissues including normal and malignant
epithelial cells and activated macrophages, suggesting an
autocrine/paracrine function in non-calcium regulating cells
(15, 16).
Calcitriol binds to the vitamin D receptor (VDR), a nuclear
hormone receptor and transcription factor, present in most
human tissues (17). The VDR contains a ligand binding
domain (LBD) comprising one b-sheet and 13 a-helical
structures. Helix H-12 contains an activation function-2
(AF-2) domain, which forms a hydrophobic binding pocket for
vitamin D and its analogues. Vitamin D binds the ligand-binding
pocket (LBP) of VDR-LBD and triggers a conformational change
resulting in dimerization, and co-activator and co-repressor
binding. Activated VDRs bind to vitamin D receptor elements
(VDRE) within promoter and enhancer regions of target genes to
regulate gene expression. VDR-binding pattern within the
genome and the identity and number of genes targeted is
dependent upon specific cell type, with between 200-1000
vitamin D target genes per cell) (17, 18).
VDRs bind to VDREs as either homodimers or a heterodimer
with the retinoid X receptor (RXR). Basal transcription factors also
bind together with transcriptional coactivators, including: steroid
receptor coactivator‐1 (SRC‐1), glucocorticoid receptor interacting
protein‐1 (GRIP1), steroid receptor coactivator 1 (SRC-1), amplified
in breast cancer 1 (AIB-1) and glucocorticoid receptor interacting
protein (GRIP), see below). The VDR/RXR/VDRE complexFrontiers in Endocrinology | www.frontiersin.org 2modulates the epigenome via recruitment of coactivators that
increase histone acetylation and upregulate transcription. VDR/
RXR complexes also bind to VDRE in association with
co-repressors to suppress transcription of vitamin D target genes.
The VDR also interacts with chromatin modifying proteins
including BRD7 and KDM6B (19). Vitamin D signaling results in
up or down-regulation of gene expression involved in common
cellular functions. This includes proliferation, differentiation, cell
adhesion, apoptosis and autophagy and affects multiple key
biological processes, such as fibrosis, inflammation and immunity
which are commonly disrupted in disease (3, 20).
Vitamin D and the Immune System
Vitamin D has multiple effects upon cellular and humoral
immunity. On the one hand, vitamin D stimulates the innate
immune system via modulating activity of Toll-Like Receptors
(TLR). Calcitriol binds to VDRs in macrophages resulting in
increased production of antimicrobial secreted peptides such as
defensin and cathelicidin and CD14, a glycoprotein, co-receptor
for TLRs (21). Here, Th1 cytokines promote a pro-inflammatory
response. On the other hand, vitamin D down-regulates the
adaptive immune response, which may have beneficial effects,
safeguarding against autoimmunity (22) (see below). Calcitriol
inhibits B-cell activation and promotes Treg cell activity leading
to cytokine mediated activation of Th2 and suppression of Th1
cells (23). T cell activation requires induction of VDR expression
which occurs downstream of T cell receptor (TCR) signaling and
activation of the p38 map kinase pathway (24). Vitamin D
influences neutrophil and macrophage function. Neutrophil
activity is decreased (25), likely resulting in an over-all
beneficial effect in patients with COVID-19 and PDAC.
However, vitamin D increases formation of neutrophil
extracellular traps (NET), meshes composed of DNA fibers,
histones and proteolytic enzymes. It is postulated that NETs
may result in detrimental effects in patients with COVID-19 and
PDAC) (26, 27) (see below). Alternatively, another group report
vitamin D reduced expression of proinflammatory cytokines and
inhibited NET formation, an effect seen only at low dose (28).
Divergent findings between these studies may reflect the animal
model used and differences between doses. Vitamin D also
influences macrophage function; an initial pro-inflammatory,
anti-tumor M1 phenotype is converted into immune-
suppressive, pro-tumor M2 macrophages.
Vitamin D signaling is controlled through a feedback
mechanism. VDR activation up-regulates CYP24A1 expression,
encoding vitamin D3 24-hydroxylase an enzyme that inactivates
calcidiol and calcitriol, in a reaction dependent upon cytochrome
P450. This reaction occurs in the liver and kidneys and prevents
toxicity at physiological levels of vitamin D (20, 29). VDRs also
localize in the membrane and mediate non-genomic actions,
with ligand-dependent effects on signal transduction, affecting
kinase and phosphatase activity. Calcitriol interacts with
membrane VDR (mVDR, also known as membrane-associated
rapid response steroid-binding proteins (1,25-MARRS). mVDR
signals via mitogen-activated protein kinase (MAPK) and cyclic
AMP (cAMP). Nevertheless, many of these effects only occur atMarch 2021 | Volume 12 | Article 644298
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significance of these pathways remains uncertain (18, 29).
Vitamin D and Physical Activity
Many factors combine to regulate vitamin D levels (see below),
and these may include several less well-knownmechanisms. Data
from the ARIC study (10,342 participants) suggest physical
exercise is associated with increased serum calcidiol. Vitamin
D deficiency (<20 ng/mL) was significantly reduced in
individuals meeting levels of physical activity recommended by
the American Heart Association (30).
Recent data suggest physical exercise increases immunity and
decreases the risk of cancer. Leisure-time physical activity was
associated with decreased rates in 13 out of 26 cancers studied,
although, melanoma and prostate cancer were exceptions with
increased risk (31). The effect in infectious disease is less certain,
although, physical activity has also been suggested to offer benefit
against COVID-19 (32, 33). The benefits of physical activity are
likely multifactorial, but may include increased levels of vitamin
D, however, it is difficult to rule out effects of reverse causation in
such studies.VITAMIN D SUPERAGONISTS
More than 3000 vitamin D analogues (VAD) have been
synthetized, most directly derived from calcitriol and
containing a variety of modifications. The aim has been to
produce analogues with enhanced VDR binding and increased
stability to metabolism. The structure of these compounds has
been described previously and a further detailed description is
beyond the scope of this review (34). Structural modifications
within vitamin D have typically been made in four sites: the side
chain, A-ring, CD-ring and triene system. More recently non-
steroidal vitamin D mimics have also been described (34). To
date, there have been few comparative studies of vitamin D and
VDSAs in clinical trials. Most data derive from in vitro studies
and animal models. Vitamin D analogues have been
characterized using in vitro assays, including VDR binding
affinity, reporter gene assays, and cellular assays for anti-
proliferative effects and enhanced differentiation. However,
since reporter gene assays may be influenced by analogue
uptake and metabolism, further analysis of VDAs in yeast or
cell-free transcription may be required to demonstrate increased
activity (35).
Vitamin D superagonists (VDSA) demonstrate a significantly
increased activity compared to calcitriol. Increased physiological
effects are seen in cellular assays for anti-proliferative effects and
enhanced differentiation. VDSAs also increase transcriptional
activity in assays using reporter gene inserted downstream of
promoters containing VDRE. Mechanisms for superagonist
properties may include: (1) enhanced VDR-RXR dimerization,
(2) increased co-activator recruitment and (3) reduced sensitivity
to metabolism (36, 37).
Various VDR coactivators have been described. These include
VDR Interacting Protein (DRIP205), also known as MED1Frontiers in Endocrinology | www.frontiersin.org 3(mediator of RNA polymerase II transcription subunit 1),
which directly interacts with the receptor. Additional
interactions occurring with coactivators: SRC-1, AIB-1 and
GRIP, have been described (38). Interestingly, many analogues
displaying selective co-activator recruitment also demonstrate an
enhanced tissue selectivity for activity. Here, tissue specific effects
may arise secondary to preferential VDA VDR/RXR complex
binding to VDREs in promoters upstream of target gene, as has
been suggested for the IP9 type of VDRE (37, 39).
X-ray crystallography studies of VDAs complexed with the VDR
yielded mechanistic information useful for ligand design.
Orientation within the LBP influences agonist activity, and
compounds with 20-epi side chain modifications sit inside this
pocket to promote coactivator binding, mediating transcription at
100-fold lower concentration than calcitriol (40). Various additional
side chain modifications have also generated ligands with
superagonist activity (34). Removal of C19 from within the A-
ring resulted in 19-nor vitamin D compounds (including
paricalcitol) with increased pro-differentiation and anti-
proliferative activity on cancer cells and decreased calcemic activity.
Finally, C/D ring modified derivatives such as the 14-epi-
analogs of calcitriol, including TX527 and TX522 (inecalcitol)
also show markedly increased anti-proliferative effects in in vitro
assays and lower calcemic effects compared with calcitriol.
Increased activity was associated with a tighter association of
these VDAs with coactivators SRC-1 and DRIP205, where a 10-
fold lower dose of inecalcitol was required for VDR-coactivator
interaction compared to calcitriol (40).
On the other hand, vitamin D signaling may also be enhanced
by decreasing interaction of the VDR with corepressors, resulting
in increased transcription. However, to date, VDAs inhibiting
corepressor interactions have not been described (41).
Several VDAs with enhanced efficacy have been described.
Structures containing fluorinated side chains are resistant to
degradation. These compounds, including CD578, mediate
increased VDR-coactivator binding and stronger pro-differentiation
activity compared to vitamin D in vitro. Fluorination stabilizes H12
resulting in enhanced binding to SRC-1, for VDR/CD578 compared
to VDR/calcitriol (42).
More recently, Corcoran et al. (43) also describe double-point
modified VDAs, derived from calcitriol with superagonist
activity. Compared to calcitriol, these compounds are less
calcemic with lower toxicity (resulting in less weight loss in
experimental animals) and mediate more than ten-fold increased
pro-differentiation effects in keratinocyte (HaCat) and acute
myeloid leukemia (HL60) cell lines.
Finally, a group in China reported the synthesis of novel VDR
ligands with non-secosteroidal structures based upon a phenyl
pyrrolyl pentane backbone. Preclinical studies suggest some of
these (including compound I5) may be useful for treatment of
patients with pancreatic cancer [(44); discussed below].
VDAs have also been identified using high throughput
screening of chemical compound libraries and in silico
screening methods (45, 46) assayed a set of 21 potential VDAs
previously identified by high throughput screening of a 10K
chemical compound library (the Tox21 qHTS data set).March 2021 | Volume 12 | Article 644298
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chemicals displayed VDA activity. Most of these compounds
induced VDR signaling via effects upon heterodimerization with
RXRa and coactivator and corepressor recruitment (46).PATHOLOGY OF VITAMIN D
Traditionally recognized for its role in childhood rickets and
adult osteomalacia, there is a growing recognition that vitamin D
deficiency may confer increased risk in multiple additional
conditions, ranging from COVID-19 to cancer (20, 47, 48).
Several extra-skeletal roles for vitamin D are recognized, but
this has resulted in only a small number of therapeutic options
using vitamin D agonists. Patients with chronic renal failure and
secondary hyperparathyroidism have been treated with
paricalcitol (49) and plaque psoriasis with topical calcipotriol
(50). Epidemiological data and preclinical studies suggest that
vitamin D deficiency may play a role in multiple common
diseases such as cancer, coronary artery disease, fibrosis and
infectious and autoimmune diseases (12, 20). Hence there is
much current interest regarding possible beneficial effects of
vitamin D supplementation. In addition, a new idea is emerging
that VDAs may offer new therapeutic avenues for several
common diseases.
Autoimmunity
Consistent with its role in inhibition of the acquired immune
response, vitamin D seems likely to decrease risk of autoimmune
diseases (including diabetes mellitus type 1 (51), multiple
sclerosis (MS) and systemic lupus erythematosus) and immune
mediated diseases such as inflammatory bowel disease (IBD).
Epidemiological and preclinical data support a role for vitamin D
in MS. Interestingly, calcitriol reduced demyelination in
experimental autoimmune encephalomyelitis (EAM) a mouse
model of MS. This was associated with increased Treg activity,
activation of Th2 and suppression of Th1 cells (52). However, a
therapeutic role in IBD and autoimmune diseases including MS
has been limited due to hypercalcemia of vitamin D at doses
required for treatment (20, 53).
Musculoskeletal Conditions
Vitamin D protects against fracture risk through several
mechanisms, including effects upon bone, muscle strength and
immunoregulation. Multiple studies find a positive association
between serum calcidiol and bone mineral density. Moreover,
vitamin D directly affects muscle function to decrease risk of falls.
Finally, osteoporosis appears to be initiated by pro-inflammatory
cytokines, driving increased bone metabolism and vitamin D
may down-regulate inflammation through effects upon the
immune system thereby decreasing risk of fracture (54, 55).
Numerous epidemiological studies have analyzed serum
calcidiol and risk of osteoporotic fractures. The data is
conflicting with some studies showing support for a protective
effect (56, 57). Consistent with this idea, several interventional
trials of vitamin D indicate a reduced risk of fracture (54).Frontiers in Endocrinology | www.frontiersin.org 4Furthermore, a meta-analysis of supplementation (vitamin D
plus calcium) versus fracture risk, found a significant reduction
in total fractures and concluded vitamin D to be a useful
preventative intervention for fracture risk reduction (58).
Finally, a recent meta-analysis of 41,738 patients studied the
correlation between serum calcidiol and risk of senile
osteoporotic fractures. High serum levels were associated with
a reduced risk of hip fractures in elderly patients, but not with
reduction in total fracture risk. The authors suggested that
disparate results seen in earlier studies may have arisen due to
selection of fracture sites studied and analysis of both
perimenopausal and senile osteoporotic fractures (59).
Fibrosis
Pathological fibrosis occurs in multiple diseases. Following
repetitive injury there is a replacement of parenchyma by scar
like tissue, resembling an unhealed wound. Occurring in tissues
such as the liver (associated with alcohol and chronic viral
infections) and kidney, fibrosis is driven by release of TGF-b
from macrophages or damaged parenchymal cells, together with
growth factors (such as CTGF and PDGF). These mediators
activate signal transduction pathways in stromal cells and
increase production of the extracellular matrix (ECM). TGF-b
signaling mediates phosphorylation of SMAD2 and SMAD3.
Then a SMAD2/3/4 complex translocates into the nucleus, binds
to SMAD-binding elements and drives expression of pro-fibrotic
genes (60).
The VDR directly interacts with SMAD3 and inhibits TGF-b-
SMAD signal transduction, an effect that is independent of VDR-
mediated transcription (60, 61) found calcitriol inhibited TGF-b
upregulation of pro-fibrotic genes in mouse kidney epithelial
cells, and reduced plasminogen activator inhibitor–1 and a-SMA
expression. These same authors went on to synthesize two VDAs
that inhibited TGF-b without activation of classical VDR gene
expression. They found 1,25-lactone and two synthetic
derivatives of 1,25-lactone (DLAMs) inhibited pro-fibrotic
signals without hypercalcemia. X-ray crystallography found
1,25-lactone and DLAMs interaction with the H12 helix
differed from calcitriol, providing a mechanistic explanation
for their properties and a template for further attempts to
design therapeutically useful new VDAs. The authors suggested
that selective VDAs may prove useful for anti-fibrosis treatments
(60, 61).
Work from Evans and colleagues found that quiescent hepatic
stellate cells (HSC) rapidly expanded following tissue injury,
resulting in fibrosis in murine liver. This response was inhibited
by VDA calcipotriol (62). Interestingly, vitamin D receptor
knock out (VDRKO) mice developed spontaneous liver
fibrosis. Moreover, activation of VDR signaling inhibited
TGFb-SMAD-dependent transcription of pro-fibrotic genes in
HSCs. The authors suggested VDR ligands might be a potential
therapy in liver fibrosis (62). A similar effect was seen for
pancreatic stellate cells (PSCs) with calcipotriol repression of
chronic pancreatitis in a mouse model (63). Furthermore, a
number of other groups have found VDA inhibition of fibrosis
in additional tissues using animal models in heart, kidney and
skin [reviewed in (13) and references within].March 2021 | Volume 12 | Article 644298
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renal disease, colon and pancreatic cancer (associated with
cancer associated fibroblasts (CAF) and in the lungs of patients
with COVID-19 that develop ARDS (discussed below). Vitamin
D inhibition of the TGF-b-SMAD signaling pathway may offer a
useful therapeutic approach in such patients.
Infectious Disease
It has been suggested that low vitamin D status confers an
increased risk of viral respiratory infections, including
influenza (20). Some preclinical studies support this idea.
Incubation of primary human bronchial epithelial cells with
calcitriol in vitro increased secretion of pro-inflammatory
cytokines CXCL8 and CXCL10. Such cytokines might be
expected to recruit macrophages and play a role in antiviral
responses (64). A protective role for vitamin D supplementation
in patients with respiratory infections still remains controversial.
A meta-analysis found reduced risk of acute upper and lower
respiratory tract infections after supplementation (65). A recent
randomly controlled clinical trial found a positive effect for
vitamin D in patients with influenza (66). However, some
other studies found no significant effect, and in one clinical
trial the duration of symptoms was increased compared to
placebo controls [(67); reviewed in (68)]. Vitamin D inhibited
lung fibrosis in several mouse models and may have therapeutic
potential in idiopathic pulmonary fibrosis (2). Much current
interest concerns the putative protective role of vitamin D in
pathogenesis of COVID-19.COVID-19
COVID-19 (coronavirus disease 2019) is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus
is closely related to several bat coronaviruses and it seems likely
COVID-19 began as a zoonotic disease, with subsequent
development of transmission between humans. Following
initial isolation of SARS-CoV-2 in Wuhan (China), COVID-
19 has now become pandemic (69). Globally, on the 30th
October, 2020, there were 44,592,789 confirmed cases of
COVID-19, including 1,175,553 deaths (The world health
organization (WHO) interactive Dashboard COVID-19 web
site. Available from: www.WHO.INT, 2020); meanwhile,
interactive web-based methods continue to track the progress
of COVID-19 (70).
The SARS-CoV-2 receptor is angiotensin-converting enzyme
2 (ACE2), mediating viral entry together with TMPRSS2
protease activity (71). Alveolar type II epithelial cells and
enterocytes are primary targets for infection, and damage to
heart, lung, liver and kidney (organs expressing ACE2) is largely
responsible for mortality in patients with COVID-19 (72). The
severity of COVID-19 corresponds to the degree of host immune
response against the virus. Infection results in effects ranging
from: asymptomatic to mild respiratory symptoms (most
commonly), severe lung injury (viral pneumonia and ARDS),
followed by septic shock, and multiple organ failure. AmongFrontiers in Endocrinology | www.frontiersin.org 5patients presenting with COVID-19 in Wuhan (China), ARDS
occurred in 42% of those with severe pneumonia, and in 61–81%
of cases admitted into intensive care (73, 74); a separate Chinese
study reported deaths of around 65% of patients with ARDS (75).
Evidence for a Protective Role for Vitamin
D in COVID-19
Evidence from multiple sources is accumulating to suggest a
protective role for vitamin D against COVID-19 (48). Indirect
evidence suggests populations predicted to be vitamin D
insufficient/deficient have higher rates of infection and severity
of COVID-19. This includes individuals with diabetes,
hypertension and obesity, all associated with low vitamin D
status and increased COVID-19 mortality (76). Serum calcidiol
concentration is dependent upon solar irradiation. Hence
mortality is increased in people of color, with more melanized
skin and proportionally reduced rates of vitamin D synthesis.
This includes BAME individuals in the UK and African
Americans in the USA (9, 10). Consistent with this, a small
study of 392 health workers in Birmingham, (UK), found
increased rates of seroconversion in patients with BAME
ethnicity was associated with deficiency (< 30 nmol/l) of
vitamin D (77). Nevertheless, other possible explanations
cannot be excluded, perhaps including differences in
socioeconomic factors (78–80).
Also consistent with this idea, latitude has been associated
with COVID-19 mortality, likely related to rate of UV mediated
cutaneous synthesis of vitamin D (76). Moreover, a comparative
study across 20 European nations found a significant negative
correlation between mean vitamin D level and COVID-19
related mortality comparing countries (81). However, such
ecological approaches have been criticized, since confounding
factors (including local screening methods and detection of
COVID-19 cases) will make analysis difficult (82).
Studies, linking vitamin D status and outcome in patients
with COVID-19 are summarized in Table 1. Most studies
have been retrospective with small patient numbers. Serum
vitamin D was correlated with outcome (biochemical, imaging
and clinical, depending upon the study) in patients with
COVID-19. Both the time of testing of serum vitamin D
(sometimes years before COVID-19 infection; see below)
and the cut off for vitamin D insufficiency/deficiency varied
between studies.
Most studies found low vitamin D status was associated with
increased disease severity and risk of mortality; this was
confirmed by a recent meta-analysis (97). On the other hand,
some reports have found no evidence for a protective role for
vitamin D (48, 86), and a large UK Biobank study (93).
Grant and McDonnell questioned whether the multivariate
analysis in the UK Biobank study was over adjusted for
confounding variables. Furthermore, they posited that
protective effects may not have been seen in the study due to
low serum vitamin D in the majority of participants (98). Finally,
in this study, vitamin D was assayed 10-14 years prior to the
COVID-19 pandemic. Hence it was questioned whether serum
levels would remain unchanged and be a useful indicator forMarch 2021 | Volume 12 | Article 644298
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acute inflammatory diseases (likely including COVID-19) may
affect serum calcidiol levels. Hence measurements at time of
diagnosis may be less reliable than seasonally adjusted
samples (101).
A quasi-experimental study found that survival was increased
in frail elderly patients where there had been regular
supplementation of vitamin D in the year preceding COVID-
19 infection (96). Finally, Entrenas Castillo and colleagues report
a small, pilot clinical trial in patients with COVID-19, where high
dose oral calcidiol reduced the requirement for admission into
intensive care (102).
Supplementation with vitamin D appears to protects against
COVID-19. Counterintuitively, vitamin D increases ACE2 and
facilitates SARS-CoV-2 entry. However, protective effects may be
part explained by vitamin D stimulation of the innate immune
system, with possible additional effects upon the renin–
angiotensin system (RAS). SARS-CoV-2 binding to ACE2
drives an increase in ACE activity and angiotensin IIFrontiers in Endocrinology | www.frontiersin.org 6production, resulting in vasoconstriction, pulmonary edema
and increased severity of COVID-19. Calcitriol may play a
protective role here via induction of ACE2 expression and
inhibition of renin activity (103–105). Interactions between
RAS and vitamin D in advanced COVID-19 are further
discussed [see below and shown in Figure 1 (function B)].
Taken together, the data strongly suggest vitamin D plays a
protective role in patients with COVID infection and may
decrease severity of ARDS. However, this hypothesis remains
unconfirmed and data from a number of on-going clinical trials
of vitamin D supplementation is eagerly awaited in order to
better answer this question [Table 2 and reviewed in (21)].ACUTE RESPIRATORY
DISTRESS SYNDROME
For the purpose of description ARDS may be separated into
acute and late phases (106). Vitamin D may be detrimental inTABLE 1 | Observational studies, linking vitamin D status with outcome (severity of disease and mortality) in patients with COVID-19.
Study N Design Effect Reference
Patients diagnosed with COVID-19 were investigated for serum
calcidiol and CT Thorax
73 Retrospective,
observational
Higher VDa associated with reduced lung involvement and
better outcome. VDDb associated with increased risk of
mortality.
(83)
Patients ≥65 years, COVID-19 positive. Groups: VDD
(≤30 nmol/L) versus VD replete. Assessed for in-hospital
mortality, requirement for NIV. Biochemistry and CT Thorax.
105 Retrospective,
observational
COVID-19-positive arm had lower serum calcidiol
compared with COVID-19-negative arm. Patient with VDD
had increased incidence of NIVc and high dependency unit
admission.
(84)
Serum calcidiol versus positive SARS-CoV-2 result. 107 Retrospective,
observational
Serum VD is significantly lower in SARS-CoV-2 positive
patients
(85)
Serum calcidiol measured in patients on day of admission and
8 weeks post PCR diagnosis of COVID-19. Results compared




VDD was common, and not an indicator of pathology seen
in CT-scans, or severity of symptoms.
(86)




VDD is associated with greater disease severity (87)
Patients diagnosed with COVID-19, investigated for serum




VDD (≤30 nmol/L) was associated with higher risk of severe
disease.
(88)
Serum calcidiol concentration versus clinical outcome and




Significant association between VD insufficiency and
increased mortality.
(89)
Serum calcidiol in COVID-19 positive and negative group 347 Retrospective,
observational
No significant difference between groups. (90)
Serum calcidiol or calcitriol measured in the year prior to
COVID-19 testing versus risk of positive test.
489 Retrospective,
observational
VDD status was associated with increased COVID-19 risk. (91)
A previous serum calcidiol level was compared to risk of SARS-




Low Serum VD was associated with increased likelihood of
COVID-19 infection and hospitalization.
(92)
Serum calcidiol concentration versus SARS-CoV-2 positivity. 190,000 Retrospective,
observational
Serum VD concentration is inversely associated with SARS-
CoV-2 positivity.
(78)
Baseline serum calcidiol versus COVID-19 mortality. 341,484 Retrospective,
observational. UK
Biobank study.
No association between VD concentration and risk of
severe infection and mortality.
(93)
VDD patients diagnosed with COVID-19 received: standard
dose cholecalciferol or high dose ergocalciferol
for 5 days
4 Case series high dose VD supplementation shortened length of stay,
lowered oxygen requirement, and reduced inflammatory
marker.
(94)




VDD increases risk for COVID-19, most clearly seen in
severe infections.
(95)
Frail elderly patients, with COVID-19 infection. Received VD in 3




Survival was increased in Group 1 with regular
supplementation over the preceding year
(96)March 2021 | Volume 12 | ArtiaVD, vitamin D; bVDD, VD deficiency; cNIV, Non-invasive ventilation; dIMV, invasive mechanical ventilation.cle 644298
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Conversely, it may be beneficial in patients with advanced
COVID-19. Attenuation of the immune response likely
prevents the cytokine storm and may decrease the severity of
ARDS (13, 14). Here we consider predicted protective roles for
vitamin D within each stage.
Acute Phase
SARS-CoV-2 grows rapidly and damages lung tissue. During
the first few days there is an influx of neutrophils and
macrophages into the alveolar space resulting in alveolitis and
loss of an intact alveolar epithelial barrier. This leads to intra
alveolar edema and hyaline membranes are deposited onto
basement membranes resulting in diffuse alveolar damage
(DAD) characteristic of ARDS (107). Here, vitamin D delays
pathology by decreasing neutrophil activity and maintains
integrity of airway epithelial cell tight-junctions by up-
regulation of occludin and claudin-5 in tight junctions. The
inflammatory cell infiltrate produces proinflammatory
cytokines and chemokines, constituting a cytokine storm that
drives development of ARDS. Vitamin D protects against
development of ARDS by inhibiting release of cytokinesFrontiers in Endocrinology | www.frontiersin.org 7(including IL-6, IFN-g, IL-1b) and chemokines such as
CXCL8 and CXCL10 (21, 106). On the other hand, vitamin D
increases NET formation and this has been suggested to
contribute to severity of pulmonary inflammation (108).
Late Phase
The late phase of ARDS (7 to 10 days after initial injury) is
dominated by a fibro-proliferative process that fills the alveoli
with granulation tissue, with increased ECM production and
proliferation of myofibroblasts and type II alveolar cells. This is
followed by irreversible pulmonary fibrosis (Figure 1). The
renin‐angiotensin system (RAS) plays a role in development of
ARDS. Two signaling pathways downstream of ACE and ACE2
play competing roles. The ACE2/Ang 1-7/MasR axis signals are
anti-inflammatory and anti-fibrotic, whereas the ACE/Ang II/
AT1R axis drives inflammation, fibrosis and vasoconstriction.
ARDS pathology is driven by the second pathway, via
unregulated Ang II, largely derived from lung fibroblasts and
activated macrophages. Ang II then stimulates activation of lung
myofibroblasts (109, 110). Vitamin D is protective, it reduces
Ang II production and increases ACE2/Ang 1-7/MasR signaling,
which may prevent the cytokine storm and inhibit developmentFIGURE 1 | Signaling pathways in late phase ARDS in patients with COVID-19; role of vitamin D Disease progression is influenced by stromal/inflammatory infiltrate.
Epithelial cells are colored blue, lung stellate cells (yellow), lymphocytes (green), and myeloid cells: macrophages M1, M2 and neutrophils (grey). SARS-CoV-2
infected alveolar type II epithelial (ATE2) cells release IL8, recruiting inflammatory cells, with neutrophil secretion of IL-6 contributing to the cytokine storm. Lung
fibrosis occurs via two pathways. Macrophages and lung stellate cells secrete angiotensin II, promoting myofibroblast formation and increasing ECM formation with
hyaline membrane disease. ATE2 cells secrete TGF-b, which drives the myofibroblast phenotype. Predicted effects of vitamin D are labeled in red A–J as described
in Table 6, where labels indicate: B: Increased ACE/Ang II/AT1R signaling; C: Down-regulation of TGF-b-SMAD-dependent transcription; D: Inhibition of pro-
inflammatory chemokine release; E: Increased antimicrobial peptides, defensins and cathelicidin; F: Maintains epithelial cell tight-junction integrity; G: Increased Treg
activity; J: Decreased Neutrophil activity and increased NET formation. VDA effects D and E are likely more relevant in early stage COVID-19 respiratory tract
infections.March 2021 | Volume 12 | Article 644298
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aggravate ARDS (111).
As discussed previously, VDAs inhibit TGFb-SMAD-dependent
transcription of pro-fibrotic and pro-inflammatory genes by
transcriptional interference with Smad2/3 in the liver [(62); see
above] and pancreas (63, 112) (see below). This same mechanism
likely also operates in pulmonary disease, particularly given the
recent identification of lung stellate cells, suggesting that anti-
fibrotic agents such as paricalcitol may be beneficial in patients
with ARDS (13).
Current clinical trials of vitamin D in patients with COVID-19
are summarized in Table 2. Most trials utilize oral vitamin D. Doses
of vitamin D range from a single dose of 25,000 IU (NCT04334005)
to 50,000 IU of vitamin D, once weekly for 2 weeks
(NCT04363840). Liu et al. (113) suggested that a single large dose
of vitamin D (300,000 IU) may be used for treatment of COVID-19.
Finally, Evans and Lippman suggest that paricalcitol might be an
effective treatment for patients with COVID-19 (13).CANCER
Vitamin D influences carcinogenesis via several mechanisms,
including: (a) promotion of differentiation and inhibition of the
epithelial mesenchymal transition, (b) regulation of cancer stem
cells, (c) reprogramming of gene expression and induction of
quiescence in cancer associated fibroblasts (CAFs), and (d)
modulation of immune response (63, 114, 115). ObservationalFrontiers in Endocrinology | www.frontiersin.org 8studies suggest low vitamin D status is associated with an
increased risk of cancer incidence and mortality (12, 116).
Consistent with this idea, earlier studies found a significant
inverse correlation between UVB irradiation and mortality
rates for several cancers (117, 118).
Cancer and Vitamin D
Supplementation Studies
A large vitamin D intervention, random control clinical trial
(VITAL) did not find a significant reduction in the primary end
point of cancer mortality (119). Subsequent analysis found
evidence for a protective effect; a second analysis of the data
suggested decreased cancer mortality in some subgroups of
enrolled individuals receiving vitamin D (18, 120). Very
recently, a further analysis of the VITAL data suggests that
vitamin D reduces the risk of metastatic or fatal cancer (121).
Apparently consistent with this idea, a meta-analysis of 10
clinical trials (81362 pooled participants) found vitamin D
supplementation was associated with a significantly lower risk
of cancer mortality (47). Finally, a meta-analyses of clinical trials,
testing high dose vitamin D supplementation (6537
participants), found a significant decrease in cancer mortality,
although, there was no reduction in cancer incidence (122).
Interestingly, several large scale studies, collectively indicate a
greater effect upon progression rather than protection against
carcinogenesis, consistent with previous reports (123).
Studies focusing on specific malignancies may provide a more
homogenous data set for analysis. Here we describe vitamin DTABLE 2 | Representative interventional clinical trials investigating Vitamin D in patients with COVID-19.
Study identifier: Study
design




bVD oral loading dose of 100,000 IU + 10000 IU VD weekly. Endpoint
incidence of COVID-19 infection.













Daily VD for 4 weeks. Endpoints: hospitalization and/or death, risk of
infection in household member.






Calcidiol, 25 mcg once daily for 2 months. Endpoints:
ARM 1 incidence of infection, severity of disease,
hospitalization and death.
ARM 2 severity and death.
1500 ARM 1 Prevention in HCWs. and





VD, 25000 UI, orally, daily. For 10 weeks. Endpoints: requirement for dIAV,
eNIV and fICU admission.
200 Non-severe symptomatic, patients
infected with COVID-19.




NCT04363840 Phase 2 VD, 50,000 IU, orally once weekly for 14 days + Aspirin 81mg, each day.
Endpoint: Hospitalization.




NCT04385940 Phase 3 VD, 50,000 IU, orally,
Determine low VD (<50 nmol/L), Endpoint: disease severity, Hospitalization.








Single high dose VD (140,000 IU) plus 800 IU of VD per day versus 800 IU of
VD per day. Endpoint: Length of hospitalization





recruitingMarch 2021 | Volume 12 | ArtiaDosage/Regimen in intervention group; bVD, vitamin D; cHealth care workers (HCW); dInvasive assisted ventilation (IAV); eNon-invasive assisted ventilation (NAV); fIntensive care unit (ICU).
gVDD, VD deficiency.cle 644298
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cancers and melanoma) and clinical studies in patients with
advanced colon and pancreatic cancers.
A meta-analysis of vitamin D supplementation in breast
cancer (72,275 participants) found relative risk reduction was
below 30%, which lays within the futility boundary for the trial
(124). On the other hand, two additional studies provide
evidence suggesting vitamin D supplementation in healthy
individuals inhibits carcinogenesis and mediates a reduction in
breast cancer incidence (125, 126).
Epidemiological studies and clinical trials have investigated
the role of serum calcidiol and vitamin D supplementation on
the risk of colorectal cancer. Multiple prospective studies suggest
vitamin D deficiency is a risk factor for colorectal cancer (127).
On the other hand, vitamin D supplementation studies have
yielded mixed results. No reduction of risk was observed in the
Women’s Health Initiative, a trial in which 18,176 women
received vitamin D and 18,106 received a placebo for an
average of 7 years (128). However, the design of this study has
been questioned regarding the low dose of vitamin D (400 IU/day)
used for supplementation (129).
The role of vitamin D in melanoma is complex. A recent
meta-analysis described a positive correlation between
circulating calcidiol and risk of melanoma. Here ultraviolet B
irradiation is a major risk factor and analysis of the relationship
between serum calcidiol and melanoma is confounded by sun
exposure. Importantly, no increased risk of melanoma occurred
with vitamin D supplementation (130). Interestingly, several
recent preclinical studies have suggested 7-dehydrocholesterol
(a precursor of vitamin D) exerts anti-tumor activity in
melanoma (131).
Extensive preclinical data from cell lines grown in vitro
supports vitamin D anti-proliferative and pro-differentiation
activity in multiple cancers, including prostate cancer and
me l anoma (132 , 133 ) ; t h e s e e ff e c t s o c cu r r ed a t
supraphysiological concentrations of calcitriol (see below) (28).
Studies following the effect of vitamin D supplementation
have also been conducted in patients with cancer: during
surveillance of indolent prostate cancer and adjuvant treatment
of colon and HER2+ breast cancer (134–137).
Interestingly, in the prostate study a second biopsy
(performed after one year of vitamin D supplementation)
found a decrease in number of positive cores or Gleason score
in 55% of subjects; however, there was no significant change in
PSA (134).
A small number of studies have evaluated vitamin D
supplementation in patients with advanced cancer. The
SUNSHINE, phase II clinical trial enrolled 139, untreated
patients with colorectal cancer. Two groups received vitamin D
(either 400 or 4,000 IU per day) in combination with best
standard of care chemotherapy. This resulted in a median
progression free survival of 13 months in the high-dose group,
versus 11 months in the low-dose group (138). More definitive
data are expected from on-going clinical trials.
Finally, vitamin D levels were measured in 1267 patients with
PDAC. Pre-treatment serum, and OS were compared for patientsFrontiers in Endocrinology | www.frontiersin.org 9with sufficient (>50 nmol/L), versus deficient (<25 nmol/L)
levels. Survival was increased in patients with sufficient versus
deficient serums in early stage PDAC, but not in patients with
advanced stage PDAC (139). This interesting observational study
requires further clinical trials to determine whether vitamin D
supplementation might improve survival in patients with
pancreatic cancer (see below).
The analysis of clinical studies of nutrients like vitamin D is
complex and may require a different approach, compared to
methods commonly used to follow pharmacological responses.
Heaney focuses upon the importance of choosing a plausible
dose range centered around where inadequate to adequate status
occurs and suggests general guidelines for nutrient studies (140).
More recently, Boucher further explores Heaney’s ideas and
additional factors complicating analysis of vitamin D
supplementation studies (141); further confounding issues are
also discussed elsewhere (18, 120, 121).HYPERCALCEMIC EFFECT OF
VDR LIGANDS
Calcitriol has anti-tumor effects in animal models of various
cancer types, and further, promotes the antitumor activities of
various chemotherapeutic agents including 5FU, Gemcitabine
and Paclitaxel (Table 3). However, this has not always been
translated into clinical trials, and is thought to be largely due to
hypercalcemic properties of calcitriol, limiting doses that can be
delivered (154), but may also partly reflect deficiencies in trial
design (155).
Physiological levels of calcitriol in humans, range between
0.05–0.16nM. In animal models, anti-tumor activity of vitamin D
requires supraphysiologic levels (156), and the therapeutic
mechanism here is distinct from a simple correction of vitamin D
deficiency. Supraphysiologic levels of calcitriol result in a limiting
toxicity of hypercalcemia. This reduces dosage that can be
administered to patients and is one possible explanation for the
less marked anti-tumor effects seen in clinical trials (Table 3), as
compared to the preclinical data (Table 4) (166).
Administration of calcitriol orally (1.5-2.5mcg/day or 10.5-
17.5mcg/week) was associated with a rate of hypercalcemia of
20-30% in prostate cancer patients (156, 167). VDSAs such as
inecalcitol, which display up to 100-fold less hypercalcemic
activity, have been developed in an attempt to circumvent
this problem.
Paricalcitol demonstrates preclinical anti-tumor effects in
various cancer types and clear anti-fibrotic activity. Reiter and
colleagues found paricalcitol (but not calcitriol) inhibited fibrosis
in vivo in the mouse CCl4 model, a finding likely of particular
significance in PDAC (168).
Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) has one of the poorest
prognoses of all solid tumors. This likely reflects multiple factors,
including desmoplasia. Desmoplasia is an increase in stromal cell
proliferation of alpha smooth muscle (a-SMA) positive fibroblastsMarch 2021 | Volume 12 | Article 644298
Easty et al. Vitamin D From COVID to CancerTABLE 4 | Completed Clinical trials of VDAs in various cancer types.
Tumor, Sample
size
Delivery/Dose Drug Outcome Reference
Prostate cancer
n = 37
Rocaltrol (0.5mcg/kg) on day 1 + docetaxel (36 mg/m(2)) on day 2,
repeated weekly for 6 weeks.
Calcitriol 30/37 (81%) achieved PSA response. 22




DN-101, PO formulation, Weekly docetaxel 36 mg/m2 iv for 3 weeks of a
4-week cycle combined with either 45mcg DN-101 v placebo PO 1 day
before docetaxel.
Calcitriol Overall, PSA response rates were 63%




PO Dexamethasone, 1mg OD + 0.5mcg calcitriol at the start of week 5.
Carboplatin (Area Under the Curve (AUC) = 2) started Week 7
Calcitriol PSA response in 13 of 34 patients and had




calcitriol 0.5 µg/kg PO, 4 divided doses over 4 h on day 1 + docetaxel 36
mg/m(2) i.v. on day 2 of each treatment week and zoledronic acid 4 mg i.v.
on day 2 on the 1st and 5th week.




Escalating doses: 30, 45, 60, and 80 mcg/m(2), calcitriol iv q21, prior to
docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2)






Calcitriol 0.5 u/kg on day 1, docetaxel 36 mg/m(2) IV on day 2,
administered weekly for three consecutive weeks, and 1 week without
treatment.
Calcitriol Modest increase in TTP, 3/25 PR, 7/25
stable disease. Median TTP 15 weeks, and





PO, 10mg/day, up to 1 year Seocalcitol 2 complete response (CR), 12 stable
disease (SD), 19 progressive disease (PD).
(162)
Pancreatic
cancer n = 36
PO, 10–15mg/day x 8 week Seocalcitol No OR (163)
Prostate cancer
n = 54













PO, 4–7 µg/day for 8 weeks + taxane Paricalcitol Most women tolerated 2–3mcg/d, (up to 7
µg per day without hypercalcemia




Prostate Ca, Dunning rat model. s.c., 1mcg, 3x/week x3 weeks. Calcitriol Inhibition of tumor growth (142)
Metastatic lung disease s.c., continuous osmotic minipump rate 1
µg/kg/24 h x18 days 2.5 µl/h.
Calcitriol Prevents met lung disease (143)
Ovarian cancer, xenograft gavage v placebo, 0.3 or 1.0 mg/kg body
weight in a volume of 20mL, OD
Calcitriol Suppression of growth (144)
Breast cancer, nitrosomethylurea-
induced rat mammary tumor model.
0.25 and 1.25 mcg/kg Calcitriol Inhibition of tumor growth, Hypercalcemia (145)
Bladder cancer, xenograft s.c., mg/mouse/d, x3 days GEM (6 mg/
mouse/d, cisplatin (0.12 mg/mouse/d).
Calcitriol Enhances activity of GEM and cisplatin (146)
Pancreatic cancer xenograft i.p., 2.5 and 5 mcg kg3×/week x28days Calcitriol Inhibition of tumor growth (147)
Squamous cell Ca Xenograft i.p., 80/160/320mg/mouse/day Inecalcitol Inhibition of tumor growth, increased apoptosis,
decreased proliferation
(148)
Prostate Ca, xenograft i.p.,1300mg/kg3×/week x42days Inecalcitol 50% decrease tumor weight (149)
Prostate Ca, xenograft i.p.,0.5mg/kg every other day x45days Seocalcitol Reversal of growth stimulatory effects of PTHrP (150)
Pancreatic cancer xenograft s.c., 2.5mg/kg3×/week Paricalcitol Inhibition of tumor growth (151)
Pancreatic cancer xenograft i.p., 0.3mg/kg2×/week, x3weeks MART-10 Inhibition of tumor growth (152)
Breast cancer, nitrosomethylurea-
induced rat mammary tumor model.
i.p. Calcipotriol Inhibition of tumor growth, No Hypercalcemia (145)
UV-induced non-melanoma skin
cancer
Topical application Calcipotriol Decrease in number and area of tumors combined with
diclofenac
(153)
Pancreatic cancer, orthotopic model i.p., 60 mg/kg QDX20, +/- GEM. Calcipotriol Induced stromal remodeling, increased intratumoral
GEM, reduced tumor volume, increased survival.
(63)icle 644298
Easty et al. Vitamin D From COVID to Cancerwith increased extracellular matrix formation. Desmoplastic
stroma restricts vasculature, impeding delivery of chemotherapy
and inhibiting an immune response. In addition, reciprocal
signaling pathways occur between PDAC and PSCs and most
studies find activated PSCs facilitate PDAC growth (169, 170).
Much interest surrounds targeting PSCs and HSCs in hepatic
metastases from PDAC, the cells responsible for desmoplasia
(171). Cancers arising within the pancreatic head compress the
biliary outlet, decreasing absorption of fat soluble vitamins. The
VDR is expressed by PSCs and PDAC cells. VDAs reduce PSC
activation and are potential stromal targeting agents; there are also
putative therapeutic effects upon malignant cells (172). Consistent
with this, a genome-wide synthetic lethal screen identified VDR as
one out of 27 validated genes that sensitized pancreatic cancer cells
line (Panc1) to gemcitabine (173).
The VDR is expressed in PSCs, HSCs, and in cancer
associated fibroblasts (CAFs) derived from these cells. VDR
activation suppresses pro-fibrotic and pro-tumorigenic
properties of cancer associated fibroblasts (CAFs). Moreover,
spontaneous pancreatic fibrosis occurs in VDR knockout mice,
consistent with a role for VDR inhibition of PSC activation (62).
Importantly, calcitriol, the naturally occurring product of
vitamin D metabolism and synthetic VDAs, inhibit tumor
growth in xenografts of pancreatic cancer (63, 151). In
addition, in preclinical studies, calcitriol potentiated cytotoxic
activity of gemcitabine in human pancreatic cancer cell line
(Capan-1) xenografts, with promotion of caspase dependent
apoptosis (Table 3). Taken together, the data suggest that
calcitriol exerts anti-fibrotic effects upon CAFs in pancreatic
cancers. However, results from clinical trials with calcitriol have
not generally demonstrated the activity expected from preclinical
studies, in part because of dose limiting hypercalcemia (161).
A combination of Calcitriol and Docetaxel in PDAC resulted
in a modest increase in time to progression, with 3/25 partial
responses (PR) and 7/25patientswith stable disease (SD), (Table 4)
(161). Recently, several new VDAs have emerged and clinical trialFrontiers in Endocrinology | www.frontiersin.org 11data suggests they may have anti-tumor effects in some specific
cancer types.
VDSAs such as calcipotriol and inecalcitol (which display up
to 100-200 fold less hypercalcemic activity) have been developed
to circumvent the problem of dose limiting hypercalcemia (164,
174). Calcipotriol induced morphological changes in PSCs, with
lipid droplet formation and decreased a-SMA expression.
Calcipotriol mediated genome-wide changes in specific gene
expression (with 664 increases and 1616 decreases), including
down-regulation of IL-6, Stromal derived factor 1 (SDF-1) and
collagen. Taken together, the data suggest that VDAs promote
PSC differentiation and quiescence. In an orthotopic mouse
model of PDAC, calcipotriol reduced desmoplasia and
enhanced anti-tumor efficacy of gemcitabine resulting in a 58%
increase in survival compared to gemcitabine alone (63). This
important study became the basis for several clinical trials testing
VDAs for anti-stromal activity in patients with PDAC (13).
A very recent study supports the data published by Evans’s
group in 2014. Using a novel VDSA they replicate some of the
original findings in an animal model of PDAC. Kang and
colleagues synthesized 57 new non-secosteroidal VDR ligands
(see above). Three of these compounds inhibited activation of
PSCs, and in combination with gemcitabine, one of these
(compound I5) demonstrated anti-tumor activity. In animal
studies I5 activity displayed similar activity to calcipotriol with
minor calcemic effects (44).
We previously planned a study testing inecalcitol (an orally
bioavailable VDSA) in combination with standard of care
gemcitabine/Nab-paclitaxel chemotherapy in patients with
advanced PDAC. Unfortunately, inecalcitol became unavailable
shortly prior to opening our Phase II clinical trial when
Hybrigenics’ discontinued production in 2018. Most studies of
VDAs in PDAC have utilized paricalcitol, which is currently the
subject of several on-going clinical trials (Table 5), including our
own recently opened Phase II study in patients with metastatic
PDAC, (ClinicalTrials.gov identifier: NCT04617067).TABLE 5 | Completed and ongoing clinical trials involving Paricalcitol in patients with PDAC.
Study identifier: Study design Dosage/Regimen/Route N Patients Status
NCT02030860 Phase I. Paricalcitol (25mcg, IV), 3x weekly, with Nab-Pac and GEM D1, 8, 15, q 28
days.
15 Neoadjuvant and post-
operatively.
Completed
NCT03520790 Phase I. Run-in safety
study and Phase II
Formulations (IV or
Oral).
Paricalcitol (25mcg, IV), 3x per week, or PO OD, with Nab-Pac and GEM D1,
8, 15, q 28 days.
112 Metastatic Recruiting





NCT03519308 Phase I. Paricalcitol, and Nivolumab with Nab-Pac and GEM D1, 8, 15, q 28 days. 20 Resectable PDAC Recruiting
NCT04054362 Phase II.
PINBALL
Nab-Pac and GEM plus or minus cisplatin, followed by Paricalcitol, 25mcg PO
(days 1, 3, 5, 8, 10, 12, 15 in a 28 day cycle)
14 Metastatic Recruiting
NCT03331562 Phase II. Pembrolizumab with paricalcitol (25mcg IV 3 xs per week) versus placebo. 24 Advanced PDAC Recruiting
NCT03415854 Phase II. Nab-Pac, GEM and Cisplatin. Plus paricalcitol Upon Disease Progression. 14 Metastatic Recruiting




Arm A: 50mcg IV weekly; Arm B: 12mcg PO once daily 20 Neoadjuvant Recruiting
NCT02930902 Phase Ib Arm A: Paricalcitol IV over D1, 8, and 15 and pembrolizumab IV d1, or Arm B:
above, plus GEM and Nab-paclitaxel IV D1, 8, and 15.
23 Neoadjuvant RecruitingMarch 2021 | Volume 12 | Article 644298
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useful stromal targeting agents in PDAC but this issue is
complicated by stromal heterogeneity (175). Two subtypes of
PSCs have been described. InflammatoryCAFs (iCAF) area-SMA
low/IL-6 high and express chemokines (CXC11 and CXC12),
whereas myofibroblast CAFs (MyCAF) are contractile, stroma
remodeling cells, with a-SMA high/IL-6 low. Reciprocal
signaling pathways between PDACs and stromal cells (myoCAFs
and iCAFs) are described in Figures 2 and 3 respectively. Within
unmanipulated surgical specimens iCAFs are located distantly
from PDAC cells, whereas myCAFs were closely juxtaposed
(181). Inhibition of iCAFs reduced PDAC volume in animal
studies, via the IL1-a pathway (IL-1R, JAK/STAT, IL-6),
suggesting these stromal cells are a useful target for stromal
therapy (180). Blockade of IL-6 signaling from inflammatory
CAFs may be a useful therapeutic avenue and results are awaited
from a phase II study (NCT02767557), testing effects of Nab-
paclitaxel and gemcitabinewithTocilizumab (an anti IL-6 receptor
monoclonal antibody) in patients with PDAC.
Gene expression studies describe subtypes of PDAC,
displaying distinct biological and clinical behaviors. ClassicalFrontiers in Endocrinology | www.frontiersin.org 12PDACs are well differentiated, respond better to 5FU based
chemotherapy, and have a better prognosis than the poorly
differentiated, basal-like subtype (182). Single cell sequencing
studies of organoids established from PDAC biopsies found
mixtures of classical and basal subtype cells coexisting within a
single tumor. Where this is the case, chemotherapy might select
for resistant subpopulations of PDAC cells and a shift in subtype
may be seen during treatment (183).
Induction of differentiation of myCAFs together with
inhibition of cytokine signaling in iCAFs might increase
therapeutic effects of chemotherapy. A combination of VDA
and a neutralizing antibody targeting signals from iCAFGs (anti
IL-6R or LIF) might improve response to current best standard
of care chemotherapy.
VDAs such as paricalcitol and calcipotriol mediate global
changes in gene expression and affect multiple pathways
(summarized in Table 6), including: (1) anti-stromal effects,
(2) direct anti-proliferative and pro-differentiation effects on
PDAC cells, and (3) effects upon the immune system.
Vitamin D results in multiple effects, some of which may be
detrimental in patients with advanced PDAC. A more recentFIGURE 2 | Reciprocal signaling pathways between PDAC and myofibroblasts (myCAFs) and role of vitamin D, modified from (169, 176, 177). Cells are colored as
in Figure 1. Epithelial (PDAC) cells are blue and stromal cells, (PSCs) are yellow. Two broad pathways are shown: a PDAC-derived secretome, including TGF-b and
Sonic hedgehog (SHH), upper and mechano-signaling via ECM/b-1 integrin and FAK (lower part of figure). TGF-b drives a myofibroblast phenotype. SHH signals via
GLI to promote dysplasia. Ligands derived from myCAFs (including IGF1, AXL, TYRO3 and TGFa) support tumor growth and inhibit apoptosis. Predicted effects of
vitamin D are labeled A-J as described in Table 6, where labels indicate: A Pro-Differentiation and Anti-Proliferation; C Inhibition of fibrosis and down-regulation of
TGF-b-SMAD-dependent transcription of pro-fibrotic genes and H Promotion of autophagy in PDAC cells and CAFs with provision of alanine to PDAC cells
(178, 179).March 2021 | Volume 12 | Article 644298
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reduced secretion of pro-tumorigenic factors PGE2, leukemia
inhibitory factor (LIF) and IL-6, consistent with the known
anti-tumor effects of VDAs (187). This was also consistent
with earlier studies that had shown LIF is secreted by PSCs,
drives tumor progression and may be a useful therapeutic
target in patients with PDAC (170). However, a new finding
was that calcipotriol reduced CD8+T cell proliferation,
decreased IFN-g and IL-17, and increased IL-10 secretion,
indicating an immunosuppressive effect (187). Furthermore,
the authors discussed the role of vitamin D inducible
peptide cathelicidin and its active cleavage product (LL-37)
in PDAC. Previous work has shown that LL-37 is associated
with cancer stem cell growth and survival in PDAC (188).
Finally, vitamin D increases NET formation and recent work
suggests this enhances hepatic micrometastasis in patients with
PDAC (192).
Paricalcitol mediates beneficial effects upon the immune
system. A pilot study of neoadjuvant paricalcitol in patients
with resectable PDAC found 10-100 fold increased T cellFrontiers in Endocrinology | www.frontiersin.org 13migration into tumors after 28 days of treatment (193).
Furthermore, a number of reviews suggest utilization of VDAs
to inhibit immune-suppressive activity of stromal cells and the
hope is that this will improve response to checkpoint inhibitors
in patients with PDAC (194, 195).
Clinical trials using paricalcitol will likely benefit most from
anti-stromal effects and subsequent improvement in delivery of
chemotherapy. Taken together, the data suggest that overall,
VDAs like calcipotriol decrease pro-inflammatory activity in
patients with PDAC (187). Thus, VDSAs in clinical trials are
predicted to result in significant benefits derived from decreased
inflammation and desmoplasia but also with detrimental effects
upon the immune system. It may be that selective agonists with
reduced activation of Treg cells, while retaining strong inhibition
of cytokine (IL-6) release will be particularly beneficial in
patients with pancreatic cancer (Table 6; Figure 3).
PDAC subtype is influenced by intrinsic (genetics and
epigenetics) and extrinsic factors, including chemotherapy and the
stromal/inflammatory infiltrate. Inhibition of TAM and neutrophil
activities result in a shift from basal to classical subtype. Finally,FIGURE 3 | Reciprocal signaling pathways within PDAC and iCAFs, modified from (170, 180) and role of vitamin D. Tumor cell interactions with immune cells (tumor
associated macrophages (TAM), neutrophils and T cells are also indicated. Cells are colored as in Figures 1 and 2. Stromal/inflammatory signaling pathways
influence PDAC progression. Growth of PDAC cells is driven by cytokines and growth factors: LIF, IL-6 and SAA1 (derived from iCAFs), IL-4 (from TH2) and TGFa
from TAMs. PDAC cells secrete IL-1a or TGF to drive an iCAF or myo-CAF phenotype. VDAs have direct effects upon cancer, stromal and immune cells and indirect
effects upon intercellular signaling pathways. Predicted effects of vitamin D are labeled A-J as described in Table 6, where labels indicate: D Inhibition of cytokine
and pro-inflammatory chemokine release; E Increased macrophage production of cathelicidin and cleavage product (LL-37), associated with a cancer stem cell
phenotype; G Suppression of immunity: increased Treg activity, activation of Th2 and suppression of Th1 cells; I Anti-tumor M1 phenotype conversion into immune-
suppressive, pro-tumor M2 macrophages, and J Decreased neutrophil activity and increased formation of NETs. The role of vitamin D in NET formation remains
controversial and is discussed above. All figures, tables, and images will be published under a Creative Commons CC-BY license, and permission must be obtained
for use of copyrighted material from other sources (including re-published/adapted/modified/partial figures and images from the internet). It is the responsibility of the
authors to acquire the licenses, follow any citation instructions requested by third-party rights holders, and cover any supplementary charges.March 2021 | Volume 12 | Article 644298
Easty et al. Vitamin D From COVID to Cancercurrent interest surrounds the role of super enhancers in PDAC. In
preclinical studies inhibition of BET family members resulted in a
shift from basal to classical subtype, likely involving down-
regulation of P63 (196, 197). It may be that BET inhibitors will
sensitize basal subtype tumors to combined anti-stromal therapy
and chemotherapy, suggesting new therapeutic approaches.DISCUSSION AND PERSPECTIVES
There is a growing recognition for the importance of extra-
skeletal roles of vitamin D. Several key biological processes
controlled by vitamin D are disrupted in common diseases,
and it has long been anticipated this might provide new
therapeutic targets. Efforts to target vitamin D signaling
pathways have focused upon (a) correction of deficiency as a
prophylactic measure to decrease disease severity, and (b) use of
VDAs as therapeutic agents in advanced disease. It is instructive
to compare the role of vitamin D signaling agents in patients with
PDAC or COVID-19 (Table 6). Most current trials in COVID-
19 have addressed early disease, whereas studies in patients with
PDAC have focused on the neoadjuvant or metastatic setting and
premalignant disease has not been targeted.
Epidemiological data suggest that vitamin D deficiency is
common and may play a role in multiple diseases including
cardiovascular and autoimmune disease (11); Fan, 2020 #276}.
Multiple studies have addressed the role of vitamin D
supplementation in extra-skeletal disease. Some, but not all,
studies found positive effects for supplementation in
respiratory infections including influenza (66, 68).
Interpretation in such studies, is complicated by disagreement
concerning serum levels of calcidiol required for sufficiency
(198), multiple confounding factors (18, 120, 121) and the
application of methods designed for testing drugs rather than
nutrients (140, 141).
Several on-going clinical trials in patients with COVID-19
address early-stage disease and prevention of infection byFrontiers in Endocrinology | www.frontiersin.org 14vitamin D (NCT04483635 and NCT04535791), other studies
have started patients onto vitamin D supplementation
immediately after COVID-19 diagnosis (NCT04536298 and
NCT04536298). No current study begins intervention in
patients with COVID-19 following development of ARDs.
Although most of these clinical trials have utilized vitamin D;
one Iranian study (NCT04386850) used calcidiol (reviewed in
(21)). Abnormal liver function tests (LFTs) are seen in 14–53% of
patients with COVID-19, perhaps reflecting expression of ACE2
in cholangiocytes (199). Calcidiol seems a good choice for
supplementation, since it does not require activation in the
liver; calcitriol might also be an effective agent. Finally, Evans
and Lippman suggest that paricalcitol might be a useful agent for
future clinical trials in COVID-19 patients (13).
In the face of new emerging viral pathogens there will
inevitably be periods without effective treatment in the time
before vaccines can be prepared. The availability of VDSAs with
anti-fibrotic activity may provide a useful approach in patients
with ARDS secondary to influenza, COVID-19, or some as yet
unknown, new viral respiratory tract infection.
Clinical trials of VDAs in pancreatic cancer have focused on
advanced stage disease. Premalignant lesions are commonly
found in patients prior to the development of PDAC. This
includes pancreatic intraepithelial neoplasia (PanIN) seen early
during PDAC development in both human pancreas and
genetically engineered mouse models. Premalignant lesions are
commonly present in patients with chronic pancreatitis with a
15-fold increased risk of PDAC (when present for more than 5
years) (200) and hereditary pancreatitis syndrome, where risk is
increased by >25-fold (201). Stromal activation and ECM
deposition occurs surrounding PanINs and it may be that
prophylactic treatment with vitamin D or VDAs would reduce
the incidence of pancreatic cancer development within these
high-risk patients.
New tools have recently become available for interpreting the
effects of stromal targeted therapy in PDAC. Firstly, gene
expression studies have identified subtypes of PDAC and
stromal cells displaying distinct biological and clinicalTABLE 6 | Predicted effects of VDAs in PDAC and COVID-19.
Vitamin D/VDA effect PDAC COVID-19 (ARDS) Reference
A Pro-Differentiation/
Anti-Proliferation
Beneficiala Uncertain (172, 184)
B Increases ACE2/Ang 1-7/MasR axis, inhibits ACE/Ang II signaling. Uncertain Beneficial (109, 110,
185)
C Inhibition of Fibrosis. Down-regulates TGFb-SMAD-dependent transcription of pro-fibrotic genes. Beneficial Beneficial (62, 63)
D Inhibition of cytokine and pro-inflammatory chemokine release. Beneficial Beneficial (63, 186)
E Increases macrophage production of antimicrobial peptides, defensins and cathelicidin Detrimentalb Beneficial (187, 188)
F Maintains integrity of epithelial cell tight-junctions Uncertain Beneficial (21)
G Suppresses immunity: increases Treg activity, activation of Th2 and suppression of Th1 cells Detrimental Beneficial (52, 187)
H Promotes Autophagy Uncertainc Uncertain (178, 179,
189)
I Pro-inflammatory, anti-tumor M1 phenotype is converted into immune-suppressive, pro-tumor M2
macrophages
Uncertaind Uncertain (75, 190)
J Decreased Neutrophil activity Beneficiale Beneficiale (21, 191)March 2021 | Volume 12aVDAs promote cancer cell and PSC differentiation. bCathelicidin active cleavage product (LL-37) is associated with PDAC stem cell growth and survival. cAutophagy occurs in CAFs and
resultant amino acids (including alanine) are made available to neighboring PDAC cells. Autophagy is likely a pro-survival mechanism in PDAC cells; dM2 polarization may contribute to
fibroproliferative phase of ARDS. eDecreased neutrophil activation is expected to be beneficial; however, the role of vitamin D in NET formation remains controversial.| Article 644298
Easty et al. Vitamin D From COVID to Cancerbehaviors, and secondly, organoids, a game-changing new
technology which allow analysis of reciprocal signaling
pathways between cancer and stromal cells. It may be that a
combination of VDSA and Tocilizumab (an IL-6 receptor
monoclonal antibody) targeting MyCAF and iCAFs will
provide a useful adjuvant to current best standard of care
chemotherapy in patients with PDAC.
Results from clinical trials testing vitamin D have often found
decreased activity compared to prior expectations based upon
preclinical studies. This has stimulated attempts to discover
VDSAs with increased efficacy and reduced calcemic effect. A
second aim has been to uncover agonists with high cell-tissue
specificity. The search for new VDSAs has used high throughput
screening of chemical libraries and computational modeling
based methods. High throughput screens are often dependent
on the promoters used to drive reporter gene readout and the cell
lines used for the assay. Hirschfeld and colleagues placed a partial
promoter sequence from the a-SMA gene upstream of a green
fluorescent reporter protein, to specify myofibroblast function
(202). The reporter gene was expressed within a rat hepatic
stellate cell line and this system might provide a valuable assay
for a high throughput screening to find VDAs with anti-fibrotic
activity. Vitamin D likely promotes a mixture of beneficial and
detrimental effects in any particular disease and consideration ofFrontiers in Endocrinology | www.frontiersin.org 15Table 6 suggests that selective agonists driving specific pathways
may be most useful for treatment. Finally, selection of VDAs
displaying decreased up-regulation of CYP24A1 expression may
result in increased activity.
A large body of evidence suggests that vitamin D and VDAs
likely possess therapeutic potential in several common diseases.
We might soon anticipate a better understanding of their role in
cancer and infectious disease. Two sets of clinical trials,
comprising 42 and 11 studies in patients with COVID-19 and
PDAC respectively, will deliver data within the next 2-3 years.
The hope is that, where such studies yield positive results, this
will act as a springboard to encourage isolation of further
effective VDSAs. Selective VDAs represent an untapped
resource for development of effective therapeutic agents. They
may be useful in multiple diseases ranging from ARDS in
patients with COVID-19 to tumor growth and metastasis in
patients with pancreatic cancer.AUTHOR CONTRIBUTIONS
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